64,277 results match your criteria Clinical Lymphoma & Myeloma [Journal]


Current Treatment Options for Breast Cancer Brain Metastases.

Curr Treat Options Oncol 2019 Feb 15;20(3):19. Epub 2019 Feb 15.

Department of Medicine, Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Ave, S73, Cleveland, OH, 44195, USA.

Opinion Statement: In the past, the standard of care for treatment of BM was whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), and surgery. There has been a greater role for medical therapies in the last two decades due to the discovery of driver mutations and corresponding targeted therapies. These innovations have dramatically altered the approach to treating these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0618-5DOI Listing
February 2019

Comorbidities (excluding lymphoma) in Sjögren's syndrome.

Rheumatology (Oxford) 2019 Feb 15. Epub 2019 Feb 15.

Rheumatology Department, Doctor Negrín University Hospital of Gran Canaria, Gran Canaria, Spain.

The information about comorbidities (excluding lymphoma) in primary Sjögren's syndrome (pSS) is relatively scarce. Cardiovascular disease, infections, musculoskeletal conditions or malignancy are likely the most relevant comorbid conditions in pSS. Different infections (particularly oral candidal infections) and fibromyalgia are extremely frequent in the daily clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/key329DOI Listing
February 2019

Innate immunity and interferons in the pathogenesis of Sjögren's syndrome.

Rheumatology (Oxford) 2019 Feb 15. Epub 2019 Feb 15.

Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Primary SS (pSS) is a rheumatic disease characterized by an immune-mediated exocrinopathy, resulting in severe dryness of eyes and mouth. Systemic symptoms include fatigue and joint pain and a subset of patients develop more severe disease with multi-organ involvement. Accumulating evidence points to involvement of innate immunity and aberrant activity of the type I IFN system in both the initiation and propagation of this disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/key360DOI Listing
February 2019

PD-L1 and tumor-associated macrophages in de novo DLBCL.

Blood Adv 2019 Feb;3(4):531-540

Oncology Biomarker Development.

Programmed death-ligand 1 (PD-L1) and its receptor, programmed cell death-1 (PD-1), are important negative regulators of immune cell activation. Therapeutically targeting PD-1/PD-L1 in diffuse large B-cell lymphoma (DLBCL) patients with a single agent has limited activity, meriting a deeper understanding of this complex biology and of available PD-L1 clinical assays. In this study, we leveraged 2 large de novo DLBCL phase 3 trials (GOYA and MAIN) to better understand the biologic and clinical relevance of PD-L1 in de novo DLBCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018020602DOI Listing
February 2019

Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial.

Clin Lymphoma Myeloma Leuk 2018 Dec 21. Epub 2018 Dec 21.

MDS Unit, AOU Careggi, University of Florence, Florence, Italy.

Background: In the phase III MDS-005 study of patients with lower-risk, non-del(5q) myelodysplastic syndromes, lenalidomide was associated with a higher rate of ≥ 8 weeks red blood cell transfusion independence (RBC-TI) compared with placebo, but also with a higher risk of hematologic adverse events (AEs).

Patients And Methods: This analysis evaluated the ratio of clinical benefit-risk in patients treated with lenalidomide or placebo, and assessed the effect of lenalidomide dose reductions on response. Clinical benefit was a composite endpoint defined as RBC-TI, transfusion reduction ≥ 4 units packed red blood cells, hemoglobin increase ≥ 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.12.012DOI Listing
December 2018

Adding Oral Pioglitazone to Standard Induction Chemotherapy of Acute Myeloid Leukemia: A Randomized Clinical Trial.

Clin Lymphoma Myeloma Leuk 2019 Jan 19. Epub 2019 Jan 19.

Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Background: The hypothesis of an effect by thiazolidinedione on leukemia cells was proposed 2 decades ago, but there is little clinical evidence regarding its efficacy. We evaluated the safety and efficacy of adding pioglitazone to standard induction chemotherapy in patients with acute myeloid leukemia (AML).

Patients And Methods: In this randomized clinical trial, newly diagnosed AML patients were randomized to 1 of 2 groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.01.006DOI Listing
January 2019

The Roles of FDG PET-CT in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy Treating Patients with Non-Hodgkin Lymphoma.

Biol Blood Marrow Transplant 2019 Feb 12. Epub 2019 Feb 12.

PET-CT Center, the First Affiliated Hospital, Zhejiang University. Electronic address:

Background: CD19-targeting chimeric antigen receptor (CAR) T cell therapy has shown great efficacy in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), but has been associated with serious adverse effects such as cytokine release syndrome (CRS). It has been speculated that NHL baseline disease burden might affect clinical outcome and CRS, but such assumption has not been explored in detail. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG), as measured by FDG PET-CT, are quantitative indicators of baseline tumor burden. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.008DOI Listing
February 2019

Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma.

Br J Haematol 2019 Feb 15. Epub 2019 Feb 15.

Section of Haematology, Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy.

Hodgkin Lymphoma (HL) is associated with deep microenvironment re-shaping and myeloid dysfunction. Given that only limited data are available regarding the role of Brentuximab Vedotin (BV) as single agent in transplant-naive relapsed/refractory (R/R) patients and its off-target effects on immune system, we evaluated the amount of regulatory T-cells (T-regs), myeloid-derived suppressor cells (MDSC) subpopulations, and their functional marker, serum arginase-1 (s-Arg-1), in peripheral blood of 15 consecutive R/R HL patients. After a median of four BV cycles, the overall response rate (complete response + partial response) was 47%, with 4 (27%) complete metabolic remissions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15801DOI Listing
February 2019

The rs61742690 (S783N) single nucleotide polymorphism is a suitable target for disrupting BCL11A-mediated foetal-to-adult globin switching.

PLoS One 2019 15;14(2):e0212492. Epub 2019 Feb 15.

Department of Genetic Research, Institute for Research and Medical Consultation (IRMC), Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.

Background: B-cell lymphoma/leukaemia 11A (BCL11A) is a C2H2-type zinc-finger transcription factor protein that is a critical modulator of haemoglobin switching and suppresses the production of foetal haemoglobin. Variation in the BCL11A gene ameliorates the severity of sickle cell disease (SCD) and β-thalassemia (β-thal). The BCL11A gene is located on chromosome 2p16. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0212492PLOS
February 2019

Driver Network as a Biomarker: Systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination prediction.

Bioinformatics 2019 Feb 15. Epub 2019 Feb 15.

Department of Systems Medicine and Bioengineering, Houston Methodist Research Institute; Weill Cornell Medicine of Cornell University, Houston, TX, USA.

Motivation: Drug combinations that simultaneously suppress multiple cancer driver signaling pathways increase therapeutic options and may reduce drug resistance. We have developed a computational systems biology tool, DrugComboExplorer, to identify driver signaling pathways and predict synergistic drug combinations by integrating the knowledge embedded in vast amounts of available pharmacogenomics and omics data.

Results: This tool generates driver signaling networks by processing DNA sequencing, gene copy number, DNA methylation, and RNA-seq data from individual cancer patients using an integrated pipeline of algorithms, including bootstrap aggregating-based Markov random field, weighted co-expression network analysis, and supervised regulatory network learning. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/bioinformatics/btz109DOI Listing
February 2019
3 Reads
4.981 Impact Factor

Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.

Br J Haematol 2019 Feb 14. Epub 2019 Feb 14.

Celgene Corporation, Summit, NJ, USA.

Chemotherapy plus rituximab has been the mainstay of treatment for follicular lymphoma (FL) for two decades but is associated with immunosuppression and relapse. In phase 2 studies, lenalidomide combined with rituximab (R ) has shown clinical synergy in front-line and relapsed/refractory FL. Here, we show that lenalidomide reactivated dysfunctional T and Natural Killer (NK) cells ex vivo from FL patients by enhancing proliferative capacity and T-helper cell type 1 (Th1) cytokine release. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15797DOI Listing
February 2019
1 Read

Development of Hepatic Steatosis After Chemotherapy for Non-Hodgkin Lymphoma.

Hepatol Commun 2019 Feb 28;3(2):220-226. Epub 2018 Dec 28.

Liver and Energy Metabolism Unit, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda MD.

Nonalcoholic fatty liver disease is the most common liver disorder in the developed world. Although typically reflecting caloric overload, it can also be secondary to drug toxicity. We aimed to describe the incidence and risk factors for steatosis during chemotherapy for non-Hodgkin lymphoma (NHL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep4.1304DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357828PMC
February 2019

Multidisciplinary team for the diagnosis and treatment of 2 cases of primary intestinal yolk sac tumor.

Cancer Biol Med 2018 Nov;15(4):461-467

Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin Medical University, Ministry of Education, Tianjin 300060, China.

Extragonadal primary yolk sac tumor of the intestinal tract origin is exceedingly rare. Through a multiple disciplinary team, the diagnosis and treatment of primary intestinal yolk sac tumor were further defined. We report 2 such cases with detailed histologic and immunohistochemical analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0054DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372916PMC
November 2018

Maintaining a methods database to optimize solid tumor tissue culture: Review of a 15-year database from a single institution.

Cancer Genet 2019 Feb 2. Epub 2019 Feb 2.

Department of Pathology and Laboratory Medicine, Clinical Genetics and Genomics Laboratories, Children's Mercy Hospital, 2401 Gillham Rd, Kansas City, MO 64108, USA; Medical School, University of Missouri Kansas City, Kansas City, MO, USA. Electronic address:

Chromosome analysis of solid tumors provides valuable information for diagnosis and patient management, yet successfully culturing solid tumors can be challenging. The Children's Mercy (CM) Cytogenetics laboratory has compiled a database of 1371 non-lymphoma solid tumors cultured since 2002. Analysis of the tumor culture data found a culture success rate of 91. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cancergen.2019.01.006DOI Listing
February 2019

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia.

J Hematol Oncol 2019 Feb 14;12(1):17. Epub 2019 Feb 14.

The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, 127 Dongming Road, Zhengzhou, 450008, China.

The current treatment for pediatric acute lymphoblastic leukemia (ALL) is highly successful with high cure rate. However, the treatment of adult ALL remains a challenge, particularly for refractory and/or relapsed (R/R) ALL. The advent of new targeted agents, blinatumomab, inotuzumab ozogamycin, and chimeric antigen receptor (CAR) T cells, are changing the treatment paradigm for ALL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-019-0705-xDOI Listing
February 2019

Rare disease knowledge enrichment through a data-driven approach.

BMC Med Inform Decis Mak 2019 Feb 14;19(1):32. Epub 2019 Feb 14.

Department of Health Sciences Research, Mayo Clinic, 205 3rd Ave SW, Rochester, MN, 55905, USA.

Background: Existing resources to assist the diagnosis of rare diseases are usually curated from the literature that can be limited for clinical use. It often takes substantial effort before the suspicion of a rare disease is even raised to utilize those resources. The primary goal of this study was to apply a data-driven approach to enrich existing rare disease resources by mining phenotype-disease associations from electronic medical record (EMR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12911-019-0752-9DOI Listing
February 2019

Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice.

BMC Cancer 2019 Feb 14;19(1):151. Epub 2019 Feb 14.

Amgen Inc., Thousand Oaks, CA, USA.

Background: Chemotherapy-induced thrombocytopenia (CIT) is a potentially serious complication that can lead to chemotherapy dose delays, dose reductions, or discontinuation, and increases the risk of serious bleeding events. The objectives of this study were to characterize the incidence, clinical consequences, and economic costs of CIT in current US clinical practice.

Methods: A retrospective cohort design and data from two US private healthcare claims repositories (01/2010-12/2016) were employed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5354-5DOI Listing
February 2019

Primary Esophageal Diffuse Large B-Cell Lymphoma: A Comparative Review of 15 Cases.

J Investig Med High Impact Case Rep 2018 Jan-Dec;6:2324709618820887

5 Abington - Jefferson Health, Abington, PA, USA.

Primary esophageal diffuse large B-cell lymphoma (DLBCL) is an extremely rare clinicopathologic entity. We report one case from our clinical experience and undertake a review of the previously published cases. A systematic literature search of the medical databases PubMed and Google Scholar was conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2324709618820887DOI Listing
February 2019

The optimal use of imaging in Radiation Therapy for lymphoma - Guidelines from the International Lymphoma Radiation Oncology Group (ILROG).

Int J Radiat Oncol Biol Phys 2019 Feb 11. Epub 2019 Feb 11.

Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Radiation therapy (RT) for the management of lymphomas has evolved over the past decades. Large extended or involved fields have been replaced by smaller involved site or nodal volumes. Currently, customized plans are created for each individual patient that encompass only the areas involved by disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2019.02.001DOI Listing
February 2019

[Central Neurological Diagnosis in Patients Infected with HIV in the Infectious Diseases Unit of University Hospital of Casablanca, Morocco].

Bull Soc Pathol Exot 2018 ;111(1):24-30

Service des maladies infectieuses, CHU de Ibn Rochd, Casablanca, Maroc.

The aim of this work is to study the epidemiology of central neurological system (CNS) diagnosed in the population of people living with HIV in the department of infectious diseases in UHC Ibn Rochd of Casablanca from January 2005 to May 2015. The demographic and clinical profile along with the outcome of these patients were studied. The data were collected from Nadis software. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3166/bspe-2018-0004DOI Listing
January 2018

Intravascular large B-cell lymphoma presenting with hearing loss and dizziness: A case report.

Medicine (Baltimore) 2019 Feb;98(7):e14470

Department of Neurology.

Rationale: Intravascular large B-cell lymphoma (IVLBCL) is a type of malignant lymphoma in which neoplastic B cells proliferate selectively within the lumina of small- and medium-sized vessels. Patients with IVLBCL frequently develop neurological manifestations during their disease course. Patients are known to often develop various neurological manifestations, but there are only a few reports of IVLBCL whose initial symptoms are deafness and/or disequilibrium. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014470DOI Listing
February 2019

Head trauma complicated with primary cranial vault lymphoma: A case report.

Medicine (Baltimore) 2019 Feb;98(7):e14465

Department of Radiology, The Second Affiliated Hospital of Dalian Medical University, Dalian.

Rationale: Primary cranial vault lymphoma (PCVL) is an extremely rare extranodal lymphoma in the skull. This case study investigates the clinical features, so as to improve the understanding of the diagnosis and therapy.

Patient Concerns: A 31-year-old male presented painful scalp mass at the site of 1-month-old head trauma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014465DOI Listing
February 2019

Effects of live music during chemotherapy in lymphoma patients: a randomized, controlled, multi-center trial.

Support Care Cancer 2019 Feb 14. Epub 2019 Feb 14.

Department of Endocrinology, Hospital of Southwest Jutland, Esbjerg, Jutland, Denmark.

Purpose: Chemotherapy is associated with both somatic and psychological side effects. Music might ease these problems. Several randomized controlled trials have investigated the effect of music, but the results are inconclusive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-019-04666-8DOI Listing
February 2019

Influence of the phenotype on mycosis fungoides prognosis, a retrospective cohort study of 160 patients.

Int J Dermatol 2019 Feb 14. Epub 2019 Feb 14.

Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada.

Background: Mycosis fungoides (MF) typically has a CD4 CD8 T-cell phenotype. Rare cases of CD4 CD8 , CD4 CD8 , or CD4 CD8 immunophenotypes have been described. Little is known about the impact of MF immunophenotypes on disease behavior. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ijd.14391
Publisher Site
http://dx.doi.org/10.1111/ijd.14391DOI Listing
February 2019
3 Reads

Long Non-coding RNA CDKN2B Antisense RNA 1 Gene Contributes to Paclitaxel Resistance in Endometrial Carcinoma.

Front Oncol 2019 29;9:27. Epub 2019 Jan 29.

School of Health Sciences, Macao Polytechnic Institute, Macau, China.

Endometrial cancer (EC) is the most common malignancy of the female reproductive tract. In this study, we clarified the clinical significance of CDKN2B antisense RNA 1 (CDKN2B-AS) gene, and its effects on paclitaxel sensitivity in EC. Firstly, CDKN2B-AS gene was highly expressed in EC tissues and cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361746PMC
January 2019

Impact of diverse chemotherapeutic agents and external factors on activation of brown adipose tissue in a large patient collective.

Sci Rep 2019 Feb 13;9(1):1901. Epub 2019 Feb 13.

Diagnostic and Interventional Radiology, Department of Radiology, Eberhard Karls University, Hoppe-Seyler-Straße 3, 72076, Tuebingen, Germany.

Increased activity of brown adipose tissue (BAT) activity in adults is thought to prevent obesity. Therefore, regulators of BAT activity might serve as anti-obesity therapy in future, but are not investigated thoroughly up to now. In our study, we assessed retrospectively the association of BAT activity with several external factors and diverse chemotherapeutic and immunosuppressive agents in a collective of 702 patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-37924-6DOI Listing
February 2019

Helicobacter pylori and nutrition: a bidirectional communication.

Minerva Gastroenterol Dietol 2019 Feb 12. Epub 2019 Feb 12.

Unit of Dietetics and Clinical Nutrition, Città della Salute e della Scienza, Turin, Italy.

Helicobacter pylori (HP) is a gram negative flagellated pathogen acid-resistant bacterium; it belongs to the order Campylobacterales that is wide spread all over the world, infecting more than 50% of the world population. HP infection is etiologically associated with non-atrophic and atrophic gastritis, peptic ulcer and with 3 to 6-fold increased relative risk for developing gastric adenocarcinoma and mucosa-associated lymphoid tissue (MA LT) lymphoma. For this reason HP is recognized by the World Health Organization as a Class I human carcinogen. Read More

View Article

Download full-text PDF

Source
https://www.minervamedica.it/index2.php?show=R08Y9999N00A190
Publisher Site
http://dx.doi.org/10.23736/S1121-421X.19.02568-6DOI Listing
February 2019
1 Read

Sinus Histiocytosis with Massive Lymphadenopathy (Rosai-Dorfman Disease) and Anaplastic Large Cell Lymphoma.

Eur J Case Rep Intern Med 2017 15;4(5):000605. Epub 2017 Mar 15.

Department of Internal Medicine, PGIMS, Rohtak, India.

Sinus histiocytosis with massive lymphadenopathy (SHML) is a rare and benign cause of lymphadenopathy and was first described in 1969. This disease commonly presents in children and young adults with supra-diaphragmatic lymphadenopathy mainly at cervical nodal sites, composed of a population of histiocytes. Since its description, over 400 cases have been described, but there are few reports in the literature on its association with lymphomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12890/2017_000605DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346787PMC

An Itchy Problem: A Clinical Case of Crusted Scabies.

Eur J Case Rep Intern Med 2017 9;4(5):000591. Epub 2017 Mar 9.

Serviço de Medicina 1, Unidade Local de Saúde do Alto Minho, EPE, Portugal.

Scabies is an infestation of the skin by the mite . A more severe form called crusted or Norwegian scabies may occur in immunosuppressed patients and the elderly. Crusted scabies mostly differs from normal scabies by the exuberance of its lesions, body distribution and high contagiousness, and requires different and more prolonged treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12890/2017_000591DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346783PMC

Intravascular Lymphoma as an Uncommon Cause of Anasarca.

Eur J Case Rep Intern Med 2016 29;3(5):000424. Epub 2016 Jun 29.

Fifth Department of Medicine, Evangelismos General Hospital, Athens, Greece.

Objectives: To report a case of intravascular lymphoma (IVL) in a Caucasian patient who presented with anasarca as his sole clinical sign.

Material And Methods: A man presented with anasarca-type oedema and fatigue. After excluding heart failure, hepatic cirrhosis, nephrotic syndrome, hypothyroidism, AL-amyloidosis and adverse drug reaction which can all cause oedema, we turned our attention to capillary permeability disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12890/2016_000424DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346965PMC

Haploinsufficiency of UNC13D increases the risk of lymphoma.

Cancer 2019 Feb 13. Epub 2019 Feb 13.

Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden.

Background: Experimental models have demonstrated that immune surveillance by cytotoxic lymphocytes can protect from spontaneous neoplasms and cancer. In humans, defective lymphocyte cytotoxicity is associated with the development of hemophagocytic lymphohistiocytosis, a hyperinflammatory syndrome. However, to the best of the authors' knowledge, the degree to which human lymphocyte cytotoxicity protects from cancer remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32011DOI Listing
February 2019

Monomorphic epitheliotropic intestinal T-cell lymphoma may mimic intestinal inflammatory disorders.

Int J Immunopathol Pharmacol 2019 Jan-Dec;33:2058738419829387

3 Department of Pharmacology, Wuhan University, Wuhan, P.R. China.

There is a significant overlap between intestinal lymphoproliferative disorders (LPDs) and inflammatory conditions of the intestine, including inflammatory bowel disease (IBD), in clinical, endoscopic, or histologic appearance, leading to diagnostic challenges. We report two cases of monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) that were initially considered to be ulcerative colitis (UC) and lymphocytic colitis, respectively. Both patients presented with diarrhea and abdominal pain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2058738419829387DOI Listing
February 2019

When a Goitre is a Thyroid Lymphoma.

Eur J Case Rep Intern Med 2018 27;5(12):000999. Epub 2018 Dec 27.

Internal Medicine Department, Centro Hospitalar e Universitário de Coimbra, Portugal.

Primary thyroid lymphoma is a rare cause of both thyroid malignancy and extra-nodal lymphoma. It typically presents as a rapidly enlarging goitre with compressive symptoms. Histological analysis of a biopsy specimen is necessary to confirm the diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12890/2018_000999DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346969PMC
December 2018

A Rare Case of Bilateral Proptosis.

Eur J Case Rep Intern Med 2018 28;5(11):000966. Epub 2018 Nov 28.

Medicine IV Department, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal.

A 65-year-old man presented with a 2-year history of severe bilateral proptosis, palpable lymphadenopathy and moderate hepatosplenomegaly. A blood test was positive for hepatitis C infection. CT showed palpebral infiltrative lesions with regional progression through the temporal and masticatory spaces to the pharynx and hypopharynx causing almost complete airway obstruction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12890/2018_000966DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346810PMC
November 2018

Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP.

J Clin Pathol 2019 Feb 12. Epub 2019 Feb 12.

Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.

Aims: Oxidative stress markers and antioxidant enzymes have previously been shown to have prognostic value and associate with adverse outcome in patients with diffuse large B cell lymphoma (DLBCL). Nuclear factor erythroid 2-related factor 1 (Nrf1) and factor 2 (Nrf2) are among the principal inducers of antioxidant enzyme production. Kelch ECH associating protein 1 (Keap1) is a negative regulator of Nrf2, and BTB (BR-C, ttk and bab) domain and CNC homolog 1 (Bach1) represses the function of both factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2018-205584DOI Listing
February 2019

Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry.

Inflamm Bowel Dis 2019 Feb 8. Epub 2019 Feb 8.

Academic Medical Center, Amsterdam, Netherlands.

Background: PYRAMID was an international multicenter, noninterventional, postmarketing registry assessing long-term safety and effectiveness of adalimumab (Humira), as used in routine clinical practice.

Methods: Adult patients with moderately to severely active Crohn's disease with or without prior adalimumab experience were enrolled in the registry and followed for up to 6 years. Effectiveness measurements included the Physician's Global Assessment (PGA, a composite of Harvey Bradshaw Index [HBI] and rectal bleeding score), clinical remission (HBI < 5), Short Inflammatory Bowel Disease Questionnaire (SIBDQ), and Work Productivity and Activity Impairment (WPAI) questionnaire. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz008DOI Listing
February 2019
2 Reads

Cytomorphological Features of Lung Adenocarcinoma with Anaplastic Lymphoma Kinase Gene Rearrangement.

J Cytol 2019 Jan-Mar;36(1):8-12

Department of Pathology, Dr. Ram Manohar Lohia, Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.

Background: The anaplastic lymphoma kinase (ALK) gene rearrangement is a predictive and prognostic marker in pulmonary adenocarcinoma. A series of clinical and pathological features have been documented in patients who harbor this translocation.

Aims: The objectives of this study were to analyze the specific cytomorphological features of lung adenocarcinoma that harbored the ALK gene rearrangement and to compare the morphological features with the mutation-negative cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/JOC.JOC_127_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343393PMC
February 2019

Immune profiling and quantitative analysis decipher the clinical role of immune checkpoint expression in the tumor immune microenvironment of DLBCL.

Cancer Immunol Res 2019 Feb 11. Epub 2019 Feb 11.

Hematopathology, The University of Texas MD Anderson Cancer Center

PD-1/L1 and CTLA-4 blockade immunotherapies have been approved for twelve types of cancer and are being studied in diffuse large B-cell lymphoma (DLBCL), the most common aggressive B-cell lymphoma. However, whether both PD-1 and CTLA-4 checkpoints are active and clinically significant in DLBCL is unknown. Whether PD-1 ligands expressed by tumor cells or by the microenvironment of DLBCL are critical for immune checkpoint is unclear. Read More

View Article

Download full-text PDF

Source
http://cancerimmunolres.aacrjournals.org/lookup/doi/10.1158/
Publisher Site
http://dx.doi.org/10.1158/2326-6066.CIR-18-0439DOI Listing
February 2019
2 Reads

Prognostic Significance of Serum Copper in Patients With Cutaneous T-cell Lymphoma.

Clin Lymphoma Myeloma Leuk 2019 Jan 2. Epub 2019 Jan 2.

University of Arizona, Tucson, AZ.

Background: Serum copper has been reported to be increased in various cancers, including lymphoma. The purpose of the present study was to investigate the clinical and prognostic importance of serum copper levels in patients with cutaneous T-cell lymphoma (CTCL).

Patients And Methods: Serum copper was measured in 60 men and 38 women with mycosis fungoides (MF) and 14 men and 3 women with erythrodermic CTCL (6 with Sézary syndrome) consecutively evaluated from July 1980 to June 1985. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650183144
Publisher Site
http://dx.doi.org/10.1016/j.clml.2018.12.020DOI Listing
January 2019
5 Reads

Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma.

Cancer Lett 2019 Feb 8. Epub 2019 Feb 8.

NHC Key Laboratory of Biotechnology of Antibiotics, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Combining antibody-drug conjugates (ADCs) with targeted small-molecule inhibitors can enhance antitumor effects beyond those attainable with monotherapy. In this study, we investigated the therapeutic combination of a CD30-targeting ADC (anti-CD30-lidamycin [LDM]) with a small-molecule inhibitor (crizotinib) of nucleophosmin-anaplastic lymphoma kinase NPM-ALK in CD30/ALK anaplastic large cell lymphoma (ALCL). In vitro, anti-CD30-LDM showed strong synergistic antiproliferative activity when combined with crizotinib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2019.02.002DOI Listing
February 2019

Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.

Am J Clin Oncol 2019 Feb 5. Epub 2019 Feb 5.

Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA.

Introduction: Anaplastic lymphoma kinase (ALK) gene rearrangements are observed in about 4% to 8% non-small cell lung cancer (NSCLC). ALK+ tumors have been associated with increased pleural and pericardial disease. Our primary objective was to determine the uncommon sites of metastasis of ALK+ NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000508DOI Listing
February 2019
1 Read

Genotyping and cytomorphological subtyping of lung adenocarcinoma based on liquid-based cytology.

Diagn Cytopathol 2019 Feb 11. Epub 2019 Feb 11.

Department of Surgery, Kyorin University School of Medicine, Tokyo, Japan.

Background: Liquid-based cytology (LBC) samples allow immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and molecular testing of nucleic acids to be performed in the remaining fixed cells. The current study aimed to examine the relationship between gene mutational status and cytomorphological features in primary lung adenocarcinoma (ADC) using LBC materials.

Methods: Forty consecutive patients with primary lung ADC underwent surgical resection in our hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/dc.24154DOI Listing
February 2019

Subconjunctival Orbital Fat Prolapse: An Update on Diagnosis and Management.

Semin Ophthalmol 2019 Feb 9:1-5. Epub 2019 Feb 9.

c Oculoplastic Department , Institut Català de Retina , Barcelona , España.

Subconjunctival prolapse of orbital fat is an uncommon clinical entity in which intraconal orbital fat herniates into the subconjunctival space. Its diagnosis is mainly clinical in character and usually based on palpation, patient clinical history, and lesion features along with a slit lamp examination. Its pathophysiology remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/08820538.2019.1576743DOI Listing
February 2019

Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma.

Eur J Haematol 2019 Feb 10. Epub 2019 Feb 10.

Department of Hematology, National Cancer Center Hospital, Tokyo, Japan, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Objective: This prospective, observational, postmarketing surveillance was conducted to evaluate the safety and effectiveness of mogamulizumab, an anti-CC chemokine receptor 4 (CCR4) monoclonal antibody, in patients with CCR4-positive, relapsed or refractory (r/r) adult T-cell leukemia-lymphoma (ATL) in Japan.

Method: All patients were scheduled to receive intravenous infusions of mogamulizumab 1.0 mg/kg once weekly for 8 weeks, alone or in combination with other modalities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13220DOI Listing
February 2019
2 Reads

Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions.

Br J Haematol 2019 Feb 10. Epub 2019 Feb 10.

Blood Cancer Research Group, Mater Research, University of Queensland, Translational Research Institute, Brisbane, QLD, Australia.

Primary mediastinal B-cell lymphoma (PMBCL) is a distinct disease closely related to classical nodular sclerosing Hodgkin lymphoma. Conventional diagnostic paradigms utilising clinical, morphological and immunophenotypical features can be challenging due to overlapping features with other B-cell lymphomas. Reliable diagnostic and prognostic biomarkers that are applicable to the conventional diagnostic laboratory are largely lacking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15778DOI Listing
February 2019
1 Read

Low Expression and Promoter Hypermethylation of the Tumour Suppressor SLIT2, are Associated with Adverse Patient Outcomes in Diffuse Large B Cell Lymphoma.

Pathol Oncol Res 2019 Feb 9. Epub 2019 Feb 9.

Institute of Cancer and Genomic Sciences, University of Birmingham, Vincent Drive, Edgbaston, Birmingham, Birmingham, B15 2TT, UK.

SLIT2 has been classified as a major tumour suppressor gene due to its frequent inactivation in different cancer types. However, alterations of SLIT2 expression and relation to patient outcomes in diffuse large B cell lymphoma (DLBCL) remain undefined. The aim of this study was to investigate the expression and the methylation status of SLIT2 gene as well as its relation to patient outcomes in DLBCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12253-019-00600-9DOI Listing
February 2019
2 Reads

Efficacy of nivolumab as checkpoint inhibitor drug on survival rate of patients with relapsed/refractory classical Hodgkin lymphoma: a meta-analysis of prospective clinical study.

Clin Transl Oncol 2019 Feb 9. Epub 2019 Feb 9.

Mother and Child Welfare Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.

Aims: The primary standard treatment for classic Hodgkin's lymphoma (cHL) is chemotherapy and radiation therapy. However, some patients get relapsed, or their diseases become resistant. PD1 blocking antibodies have been used to increase the response of treatment in solid tumors, and led to potentially stable responses that are acceptable. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12094-018-02032-4
Publisher Site
http://dx.doi.org/10.1007/s12094-018-02032-4DOI Listing
February 2019
6 Reads

[Recent Progress of Molecular Genetic Characteristics and Prognosis of Non-Hodgkin's Lymphoma--Review].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):301-305

Department of Hematology and Oncology, Putuo District People's Hospital, Zhoushan 316100, Zhejiang Province, China.

Lymphomas are traditionally divided into Hodgkin's lymphoma and non-Hodgkin's lymphoma(NHL), the NHL is a common hematological cancer, which represents a wide spectrum of illnesses from the most indolent to the most aggressive malignancies, and the detection of related molecular targets will be needed for diagosing each subtype of NHL. Advances in understanding the pathogenesis of NHL have improved the precision of diagnosis and the prognosis evaluation of patients with this disorder, such as chromosomal translocation leading to the up-regulation of oncogene expression. Besides, the deletion of several tumor suppressor genes may cause excessive proliferation in tumor cells, and the single nucleotide polymorphism (SNP) determines the differences of susceptibility, drug-resistance and prognosis of NHL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.050DOI Listing
February 2019

[Correlation of EBV Infection with Expression of TNF-α-Inducing Protein 3 Gene and A20 Protein in Hodgkin's Lmphoma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):91-95

Department of Pathology, Zhumadian Central Hospital, Zhumadian 463000, Henan Province, China.

Objective: To analyze the correlation of EBV infection with expression of TNF-α-inducing protein 3 gene and A20 protein in Hodgkin lmphoma.

Methods: The clinical data and pathological specimens of 65 cases of Hodgkin's lymphoma in our hospital were analyzed retrospectively, and the tissue chips were made for the rich area of the tumor cells. The latent membrane protein 1 encoded by EBV was measured by immunohistochemical staining, and the RNA encoded by EBV was measured by in situ hybridization to analyze the infection state. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.015DOI Listing
February 2019

[Clinicopathological Observation of Primary Renal Non-Hodgkin's Lymphoma--A Report of Two Cases].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):86-90

Department of Pathology, The Changzhou Municipal Second People's Hospital, Affiliated to Nanjing Medical University, Changzhou 213000, Jiangsu Province, China.

Objective: To investigate the clinicopathological and immunohistochemical features as well as diagnosis, differential diagnosis,treatment and prognosis of patients with primary renal non-hodgkin's lymphoma (PRNHL).

Methods: Clinical data of 2 patients with PRNHL from January 2013 to October 2017 were retrospectively analyzed.

Results: One of the two male patients PRNHL aged 51 years old, admitted to hospital for swelling and pain in the right waist, B-ultra sonic examination showed a very solid upper right renal space occupying lesion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.014DOI Listing
February 2019
2 Reads